Induction chemotherapy of modified docetaxel, cisplatin, 5-fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma

Head Neck. 2022 Sep;44(9):2018-2029. doi: 10.1002/hed.27119.

Abstract

Background: Previous studies have investigated the value of induction chemotherapy (IC) in organ preservation strategies for head and neck cancers. This study evaluated the effectiveness of sequential IC with radiotherapy as a laryngeal preservation strategy for locally advanced hypopharyngeal carcinoma (LAHSCC).

Methods: One hundred and forty-two consecutive patients with LAHSCC were retrospectively analyzed who received three IC regimens from 2015 to 2019.

Results: In the TP (docetaxel plus cisplatin), TPF (TP plus 5-fluorouracil), and TPX (TP plus capecitabine) IC groups, there were 51, 29, and 62 patients, respectively. The primary tumor objective response rates were 51%, 55.2%, and 71%, and the 3-year survival rates with preserved larynx were 36.6%, 31.8%, and 51.2%, respectively (p = 0.03). There was no difference in overall survival and the adverse events were tolerable.

Conclusions: The TPX regimen displayed good efficacy and safety, indicating its potential as a therapeutic IC regimen for LAHSCC.

Keywords: chemotherapy; fluoropyrimidine agents; laryngeal preservation; locally advanced hypopharyngeal squamous cell carcinoma; survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cisplatin / therapeutic use
  • Docetaxel / therapeutic use
  • Fluorouracil / therapeutic use
  • Head and Neck Neoplasms* / drug therapy
  • Humans
  • Induction Chemotherapy
  • Laryngeal Neoplasms* / drug therapy
  • Laryngeal Neoplasms* / pathology
  • Laryngectomy
  • Larynx* / pathology
  • Retrospective Studies
  • Squamous Cell Carcinoma of Head and Neck / drug therapy
  • Taxoids / therapeutic use

Substances

  • Taxoids
  • Docetaxel
  • Cisplatin
  • Fluorouracil